Advertisement
AKBA Novinky na Forexu
Akebia Therapeutics Resubmits NDA For Vadadustat To FDA
Biopharmaceutical company Akebia Therapeutics, Inc. (AKBA) announced Thursday it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
RTTNews
|
Před 676 dny
Akebia Therapeutics Expects To Resubmit NDA For Vadadustat NDA In Q3
Biopharmaceutical company Akebia Therapeutics, Inc. (AKBA) announced Thursday that the company expects to resubmit its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease in adult patients on dialysis by the end of the third quarter of 2023.
RTTNews
|
Před 711 dny
